Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 21   

Articles published

BOTA 5.59 +0.12 (2.19%)
price chart
Biotech Gainers: Alcobra (NASDAQ:ADHD), Biota Pharmaceuticals (NASDAQ ...
Biota Pharmaceuticals: Phase 2 trial of Laninamivir Octanoate for the treatment of influenza in adults.Biota Pharmaceuticals Inc (NASDAQ:BOTA)'s yesterday closed at $5.47. Stock institutional ownership is 19.50% while insider ownership included 15.42%.
Healthcare Bullish Stocks: Biota Pharmaceuticals (NASDAQ:BOTA), OncoGenex ...
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) presented an update on the company at the 26th Annual ROTH Conference at 12:30 p.m.
Stock Update: China Jo Jo Drugstores Inc And Biota Pharmaceuticals Inc
New York, NY - (NISMAGAZINE) - 03/24/2014 - China Jo Jo Drugstores Inc (NASDAQ:CJJD) reported a super impressive 200 percent increase in revenue that it was deriving from its online sales vertical from its 3Q operations in comparison to 3Q12.
3 Biotechs Expecting Top Line Phase 2 Data Mid 2014 [Athersys, Inc.]
When it comes to small/mid size biotech companies, it's no secret clinical data is king, often pushing the stock prices to new highs upon positive results.
Related articles »  
Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare ...
Current portfolio companies include AcelRx Pharmaceuticals (Nasdaq: ACRX), Ambit Biosciences (Nasdaq: AMBI), Biodelivery Sciences International (Nasdaq: BDSI), Biota Pharmaceuticals (Nasdaq: BOTA), Ignyta Inc (Nasdaq:RXDX), Intarcia Therapeutics, ...
Related articles »  
Venus Remedies gains on marketing nod from Venezuela
Shares of Venus Remedies gained more than 17% in intraday on Friday after the pharma company in an exchange release announced that it has recieved marketing nod from Venezuela for the injectible anti-biotic meropenem. "Company is planning to ...
Related articles »  
Europe Seed Treatment Market by Type (Chemical & Non-Chemical) worth ...
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
Related articles »  
Biota Pharmaceuticals Inc prices $25 mln public offering